CNS Neurotoxicity of Antiretrovirals

被引：74

作者：

Lanman, Tyler ^{[1
]}

Letendre, Scott ^{[2
]}

Ma, Qing ^{[3
]}

Bang, Anne ^{[4
]}

Ellis, Ronald ^{[1
]}

机构：

[1] Univ Calif San Diego, Sch Med, Dept Neurosci, 200 W Arbor Dr, La Jolla, CA 92103 USA

[2] Univ Calif San Diego, Sch Med, Dept Infect Dis, La Jolla, CA 92093 USA

[3] Univ Buffalo, Sch Pharm & Pharmaceut Sci, Pharmacotherapy Res Ctr, Buffalo, NY USA

[4] Sanford Burnham Prebys Med Discovery Inst, La Jolla, CA USA

来源：

JOURNAL OF NEUROIMMUNE PHARMACOLOGY | 2021年 / 16卷 / 01期

关键词：

Antiretroviral; Neurotoxicity; HAND; Neurocognitive; HIV; Antiretroviral therapy; HUMAN-IMMUNODEFICIENCY-VIRUS; NERVOUS-SYSTEM PENETRATION; ANTI-CD4; MONOCLONAL-ANTIBODY; RESISTANT HIV-INFECTION; SUPPRESSED CHRONIC HIV; AGE-RELATED-CHANGES; CEREBROSPINAL-FLUID; MITOCHONDRIAL TOXICITY; NEUROCOGNITIVE DISORDERS; COGNITIVE IMPAIRMENT;

D O I：

10.1007/s11481-019-09886-7

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

The development of novel antiretroviral treatments has led to a significant turning point in the fight against HIV. Although therapy leads to virologic suppression and prolonged life expectancies, HIV-associated neurocognitive disorder (HAND) remains prevalent. While various hypotheses have been proposed to explain this phenomenon, a growing body of literature explores the neurotoxic effects of antiretroviral therapy. Research to date brings into question the potential role of such medications in neurocognitive and neuropsychiatric impairment seen in HIV-positive patients. This review highlights recent findings and controversies in cellular, molecular, and clinical neurotoxicity of antiretrovirals. It explores the pathogenesis of such toxicity and relates it to clinical manifestations in each medication class. The concept of accelerated aging in persons living with HIV (PLWH) as well as potential treatments for HAND are also discussed. Ultimately, this article hopes to educate clinicians and basic scientists about the neurotoxic effects of antiretrovirals and spur future scientific investigation into this important topic.

引用

页码：130 / 143

页数：14

共 172 条

[1] Neurological and Psychiatric Adverse Effects of Antiretroviral Drugs [J].

Abers, Michael S. ;

Shandera, Wayne X. ;

Kass, Joseph S. .

CNS DRUGS, 2014, 28 (02) :131-145

[2] Host-pathogen interactions in the development of metabolic disturbances and atherosclerosis in HIV infection: The role of CCL2 genetic variants [J].

Alonso-Villaverde, Carlos ;

Aragones, Gerard ;

Beltran-Debon, Raul ;

Fernandez-Sender, Laura ;

Rull, Anna ;

Rodriguez-Sanabria, Fernando ;

Marsillach, Judit ;

Pardo-Reche, Pedro ;

Camps, Jordi ;

Joven, Jorge .

CYTOKINE, 2010, 51 (03) :251-258

[3] Updated research nosology for HIV-associated neurocognitive disorders [J].

Antinori, A. ;

Arendt, G. ;

Becker, J. T. ;

Brew, B. J. ;

Byrd, D. A. ;

Cherner, M. ;

Clifford, D. B. ;

Cinque, P. ;

Epstein, L. G. ;

Goodkin, K. ;

Gisslen, M. ;

Grant, I. ;

Heaton, R. K. ;

Joseph, J. ;

Marder, K. ;

Marra, C. M. ;

McArthur, J. C. ;

Nunn, M. ;

Price, R. W. ;

Pulliam, L. ;

Robertson, K. R. ;

Sacktor, N. ;

Valcour, V. ;

Wojna, V. E. .

NEUROLOGY, 2007, 69 (18) :1789-1799

[4] Efavirenz and the CNS: what we already know and questions that need to be answered [J].

Apostolova, Nadezda ;

Funes, Haryes A. ;

Blas-Garcia, Ana ;

Galindo, Maria J. ;

Alvarez, Angeles ;

Esplugues, Juan V. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (10) :2693-2708

[5] Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial [J].

Arenas-Pinto, Alejandro ;

Stohr, Wolfgang ;

Jager, Hans Rolf ;

Haddow, Lewis ;

Clarke, Amanda ;

Johnson, Margaret ;

Chen, Fabian ;

Winston, Alan ;

Godi, Claudia ;

Thust, Steffi ;

Trombin, Rita ;

Cairns, Janet ;

Solanky, Bhavana S. ;

Golay, Xavier ;

Paton, Nicholas I. .

CLINICAL INFECTIOUS DISEASES, 2016, 63 (02) :257-264

[6] Neuropsychiatric side effects of efavirenz therapy [J].

Arendt, Gabriele ;

de Nocker, Dominique ;

von Giesen, Hans-Juergen ;

Nolting, Thorsten .

EXPERT OPINION ON DRUG SAFETY, 2007, 6 (02) :147-154

[7] Short Communication: Aging Not Gender Is Associated with High Atazanavir Plasma Concentrations in Asian HIV-Infected Patients [J].

Avihingsanon, Anchalee ;

Kerr, Stephen J. ;

Punyawudho, Baralee ;

van der Lugt, Jasper ;

Gorowara, Meena ;

Ananworanich, Jintanat ;

Lange, Joep M. A. ;

Cooper, David A. ;

Phanuphak, Praphan ;

Burger, David M. ;

Ruxrungtham, Kiat .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2013, 29 (12) :1541-1546

[8] TEMPORAL TRENDS IN THE INCIDENCE OF HTV-1-RELATED NEUROLOGIC DISEASES - MULTICENTER AIDS COHORT STUDY, 1985-1992 [J].

BACELLAR, H ;

MUNOZ, A ;

MILLER, EN ;

COHEN, BA ;

BESLEY, D ;

SELNES, OA ;

BECKER, JT ;

MCARTHUR, JC .

NEUROLOGY, 1994, 44 (10) :1892-1900

[9] A cross-sectional study to evaluate the association of hyperbilirubinaemia on markers of cardiovascular disease, neurocognitive function, bone mineral density and renal markers in HIV-1 infected subjects on protease inhibitors [J].

Barber, T. J. ;

Moyle, G. ;

Hill, A. ;

Singh, G. Jagjit ;

Scourfield, A. ;

Yapa, H. M. ;

Waters, L. ;

Asboe, D. ;

Boffito, M. ;

Nelson, M. .

HIV CLINICAL TRIALS, 2016, 17 (03) :123-130

[10] Molecular insights into NRTI inhibition and mitochondrial toxicity revealed from a structural model of the human mitochondrial DNA polymerase [J].

Bienstock, RJ ;

Copeland, WC .

MITOCHONDRION, 2004, 4 (2-3) :203-213

← 1 2 3 4 5 6 7 8 9 10 →